Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836225 | 1.00 | KDM4E (0.56) | KDM4EGRIN2BSPHK1SLC18A3GRIN1 | |
| SCHEMBL6840853 | 0.96 | KDM4E (0.54) | KDM4EGRIN2BSPHK1SLC18A3GRIN1 | |
| SCHEMBL6840856 | 0.96 | KDM4E (0.54) | KDM4EGRIN2BSPHK1SLC18A3GRIN1 | |
| SCHEMBL7023319 | 0.95 | KDM4E (0.52) | KDM4EGRIN2BSPHK1SLC18A3GRIN1 | |
| SCHEMBL5689661 | 0.95 | KDM4E (0.52) | KDM4EGRIN2BSPHK1SLC18A3GRIN1 | |
| SCHEMBL5689666 | 0.95 | KDM4E (0.52) | KDM4EGRIN2BSPHK1SLC18A3GRIN1 | |
| SCHEMBL6836213 | 0.92 | KDM4E (0.58) | KDM4EGRIN2BSPHK1SLC18A3OPRM1 | |
| SCHEMBL6836212 | 0.92 | KDM4E (0.58) | KDM4EGRIN2BSPHK1SLC18A3OPRM1 | |
| SCHEMBL5689337 | 0.87 | SPHK1 (0.49) | KDM4EGRIN2BSPHK1 | |
| SCHEMBL5689334 | 0.87 | SPHK1 (0.49) | KDM4EGRIN2BSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225164-A1 | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-04 | — | — | US | claimed |
| US-6765022-B2 | BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS; ANTIISCHEMIC AGENTS; STROKES, PARKINSON*S DISEASE; N-METHYL-D-ASPARTATE ANTAGONISTS (NMDA) | WARNER-LAMBERT COMPANY | 2004-07-20 | — | — | US | disclosed |
| US-20030225164-A1 | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225164-A1 | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists | GRIN1, GRIN3A, GRIN2A | KDM4E 2266/4885GRIN2B 4/4885SPHK1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.